

# SZN-043 Induced Quick and Robust Hepatocyte Proliferation in a 14-Day Daily Dosing Edu-labeling Study in SCID Mice

Chenggang Lu\*, Russell B. Fletcher, Jacqueline L. Phipps, Darshini Shah, Shalaka Deshmukh, Trevor Fisher, Hélène Baribault, Wen-Chen Yeh, Yang Li

Surrozen Inc., South San Francisco, CA 94080, USA; \*Presenting author

## Background

- Wnt/ $\beta$ -catenin signaling plays a key role in hepatocyte regeneration in homeostasis and after liver injury
- R-spondins (RSPO) amplify the signal of Wnt ligands by stabilizing and increasing the amount of Wnt receptors on the cell surface
- We previously showed that our hepatocyte-targeted RSPO mimetic, SZN-043, specifically induced Wnt target gene expression in the liver and promoted hepatocyte proliferation in mice
- This study aimed to evaluate the kinetics and the overall effects of SZN-043-induced hepatocyte proliferation in a 2-week daily SZN-043 dosing schedule

## Methods


Experimental timeline for SCID mice (n=55 per group):

- Day 1:** Start of study.
- Day 2-14:** SZN-043 10mg/kg daily (blue arrow) and Anti-GFP IgG 10 mg/kg twice weekly (grey arrow).
- Drinking water:** Contains Edu 1 mg/kg (light blue arrow).
- Termination/Liver collection:** Occurs on Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14.

- Edu was used to label any proliferating nucleus as it passes through S phase
- Liver sections were co-stained for EdU, MKI67 (proliferation marker) immunofluorescence, and HNF4A (hepatocyte-specific marker) immunofluorescence, and counterstained with DAPI nuclear labeling
- The hepatocyte proliferation index (number of MKI67+/HNF4A+/DAPI+ nuclei) and the accumulated number of hepatocytes that had gone through at least one round of proliferation (EdU+/HNF4A+/DAPI+ nuclei) were quantified


## Results

Figure 1. Significant Proliferation of Hepatocytes in Response to SZN-043 Was Quick and Transient



- Significant hepatocyte proliferation was observed 48 hours after the first dose of SZN-043, reaching a peak at Day 4, followed by a rapid decline to near baseline level at Day 6 (Figure 1A). Consistently, the percent of hepatocyte nuclei that were EdU positive reached a plateau at Day 5 (Figure 1B). These together suggest that most hepatocytes stopped proliferating or incorporating EdU after this timepoint.
- These findings suggest that the hepatocytes responded quickly and robustly to SZN-043, but only underwent a limited number of proliferation cycles, despite the continued exposure to SZN-043 for up to 14 days.
- Over 50% of all hepatocytes in the SZN-043-treated group were EdU+ by study end compared to about 10% in the anti-GFP-treated group (Figure 1B), demonstrating the pharmacology effect of SZN-043 on stimulating hepatocyte regeneration.


Figure 2. Liver mRNA Expression of Axin2 was Significantly Increased with SZN-043



- Axin2 is a Wnt/ $\beta$ -catenin target gene and an indicator of SZN-043 activity in the liver.
- Liver mRNA expression of Axin2 was significantly increased with SZN-043 treatment compared to anti-GFP throughout the study, indicating that continuous dosing of SZN-043 maintained  $\beta$ -catenin signaling induction despite the low level of hepatocyte proliferation after day 5.
- This result together with Figures 1A and 1B suggested hepatocytes only go through a limited number of cell cycles when continuously exposed to SZN-043 in the 14-day study.


Mean with SD. Statistical Analyses: Two-way ANOVA, with Holm-Šidák correction. All comparisons made with the anti GFP group. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

Figure 3. Non-Hepatocyte (HNF4A-negative) Cell Proliferation was Significant with SZN-043



- Significant non-hepatocyte (HNF4A-negative) cell proliferation was also observed with SZN-043
- Proliferation of non-hepatocyte appeared to have peaked after hepatocyte proliferation
- Mostly of Kupffer cells/macrophages
  - F4/80 (macrophage and monocyte marker; red) expression peaked significantly at Day 5 compared to anti-GFP (Figure A and B). (liver sections counted stained with DAPI; white)
  - After Day 8, F4/80 expression was comparable between SZN-043 and anti-GFP, with no visible differences observed.
- Endothelial cell marker staining did not reveal differences between SZN-043 and anti-GFP groups (Figure 3C).

Mean with SD. Statistical Analyses: One-way ANOVA, Holm-Šidák test. All comparisons made with the anti GFP group. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.



- There was negligible proliferation of cholangiocytes (epithelial cells of the bile duct; labeled with CK19) with SZN-043 (Figure 3D).
- As previous studies with SZN-043 have shown no direct impact on cells other than hepatocytes (data on file), the proliferation observed in the HNF4A-negative cells in this study was likely a secondary effect in response to and in support of the increasing number of hepatocytes.

## Conclusions

- SZN-043 induced a rapid transient increase in hepatocyte proliferation, followed by a rapid decline to baseline despite continued exposure to SZN-043 and  $\beta$ -catenin signaling induction for up to 14 days.
- Hepatocyte proliferation induced by SZN-043 was self-limited and likely controlled by other mechanisms controlling cell proliferation (Sarkar A. et al., 2021).
- Proliferation observed in the HNF4A-negative cells was likely due to the tissue responding to the large number of proliferating hepatocytes.

Presenting author: Chenggang Lu, email: [chenggang@surrozen.com](mailto:chenggang@surrozen.com)  
 Surrozen Inc., South San Francisco, CA 94080 — [www.surrozen.com](http://www.surrozen.com)  
 Previously presented at Digestive Disease Week (DDW), San Diego, CA, May 21–24, 2022

CL, RBF, JLP, DS, SD, TF, HB, WY and YL are present or past employees of Surrozen, Inc. and shareholders of Surrozen stock. These materials contain forward-looking statements regarding Surrozen, Inc. (the "Company"). There can be no assurance that these forward-looking statements can or will be achieved, and the Company makes no representations or warranties as to its actual future performance. In addition, the Company makes no warranties or representations regarding the accuracy or completeness of these materials and expressly disclaims any obligation to correct, update or revise any of these materials for any reason. The recipient of these materials should conduct its own investigation and analysis of the business of the Company and the data described in these materials.